Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Project description

Innovative liposome-based drug for osteoarthritis therapy

Osteoarthritis, a degenerative disease of the joints where the protective cartilage at the ends of the bones wears down over time, affects millions of people worldwide. The EU-funded OAlipotherapy project is working towards the development of liposomes functionalised with patented novel molecules that can extend their half-life in joints by an order of magnitude following intra-articular (IA) injection. The objective is to investigate the potential for long-retention IA drug delivery using validation in animal models. The pre-commercialisation studies will involve networking, identification of potential partners and development of the business plan.

Objective

Osteoarthritis (OA) is the most widespread joint disease, affecting millions and imposing a huge individual and socio-economic burden. The creation of liposomes functionalised with novel (IP-protected) molecules that greatly extend (by almost an order of magnitude) their half-life in joints following IA injection, relative to existing approaches, and the alleviation of OA that may arise through exploiting this longer retention, is the basis of this proof of concept project. The main innovation step is functionalizing liposomes with our novel molecules to provide much longer retention drug-delivery vehicles, which therefore provide greater benefits in therapy relative to existing approaches, and so should be preferred by patients. Its practical implementation, to advance and investigate the potential for long-retention IA drug-delivery and other uses, will be carried out both through validation on animals (proof-of-concept), through suitable pre-commercialisation studies, networking and identifying potential partners, and developing a business plan. Hence, we propose to validate the concept of creating new products that will be available commercially for IA delivery, implementing the long-retention in the joints which greatly enhances their usefulness and which is the basis of the present innovation step.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-PoC

See all projects funded under this call

Host institution

WEIZMANN INSTITUTE OF SCIENCE
Net EU contribution
€ 150 000,00
Address
HERZL STREET 234
7610001 Rehovot
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 150 000,00

Beneficiaries (1)